• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by GoodRx Holdings Inc.

    5/13/26 5:00:10 PM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001336504
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    GOODRX HOLDINGS, INC.
    SEC File Number
    001-39549
    Address of Issuer
    2701 Olympic Boulevard
    Santa Monica
    CALIFORNIA
    90404
    Phone
    855 268-2822
    Name of Person for Whose Account the Securities are To Be Sold
    IAN THORNTON CLARK
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    43100111620.3810471118605/13/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/03/2025Restricted StockIssuerCheckbox not checked2585206/03/2025Not Applicable
    Common07/08/2025Restricted StockIssuerCheckbox not checked1724807/08/2025Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/13/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Ian Thornton Clark

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $GDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    2/27/2026Overweight → Neutral
    Analyst
    1/22/2026$2.75Buy → Hold
    Jefferies
    12/9/2025$3.00Underweight
    Barclays
    8/11/2025Strong Buy → Outperform
    Raymond James
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $GDRX
    SEC Filings

    View All

    SEC Form 144 filed by GoodRx Holdings Inc.

    144 - GoodRx Holdings, Inc. (0001809519) (Subject)

    5/13/26 5:00:10 PM ET
    $GDRX
    EDP Services
    Technology

    SEC Form 10-Q filed by GoodRx Holdings Inc.

    10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

    5/6/26 4:15:07 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    5/6/26 4:13:29 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

    New $14.99-per-month membership brings together free and low-cost generic medications, affordable online care visits, and savings across dental, vision, labs and imaging Brief Summary: GoodRx launched GoodRx Companion, a new $14.99-per-month subscription to lower everyday healthcare costs Provides access to free and low-cost generic medications, affordable online care, and savings on routine healthcare services Expands GoodRx's subscription strategy as consumers face tighter insurance restrictions and higher out-of-pocket healthcare cost GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today launched GoodRx Companion, a new $14.99-per-month subs

    5/27/26 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports First Quarter 2026 Results

    Pharma Direct Revenue Increased 82% Year-Over-Year in the First Quarter Company Raises Full Year 2026 Revenue and Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2026. First Quarter 2026 Highlights Revenue of $194.0 million Net income of $1.2 million; Net income margin of 0.6% Adjusted Net Income1 of $23.0 million; Adjusted Net Income Margin1 of 11.9% Adjusted EBITDA1 of $58.3 million; Adjusted EBITDA Margin1 of 30.0% Net cash provided by operating activities of $11.8 million "We deliver

    5/6/26 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients

    Eligible self-pay patients can access the oral diabetes treatment for as low as $149 per month Brief Summary: GoodRx expands access to Ozempic® pill (oral semaglutide) for as low as $149 per month Available at GoodRx's nationwide pharmacy network Adds an oral option to the Ozempic treatment portfolio GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced that it is providing access to self-pay pricing for Novo Nordisk's Ozempic® pill (oral semaglutide), helping eligible patients with type 2 diabetes obtain the medication for as low as $149 per month at pharmacies nationwide. "As Novo Nordisk brings the Ozempic pill to market, we're f

    5/1/26 8:10:00 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hirsch Douglas Joseph was granted 4,642 shares, increasing direct ownership by 2% to 247,502 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    5/29/26 5:58:56 PM ET
    $GDRX
    EDP Services
    Technology

    Director Bruehlman Ronald E was granted 4,642 shares, increasing direct ownership by 4% to 133,918 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    5/29/26 5:58:05 PM ET
    $GDRX
    EDP Services
    Technology

    Chief Accounting Officer Chan Thomas (Tc) converted options into 5,575 shares and covered exercise/tax liability with 2,838 shares, increasing direct ownership by 274% to 3,737 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    5/15/26 4:51:24 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    12/4/23 4:35:10 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/30/23 4:41:35 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/17/23 7:08:30 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GoodRx downgraded by Analyst

    Analyst downgraded GoodRx from Overweight to Neutral

    2/27/26 8:28:37 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx downgraded by Jefferies with a new price target

    Jefferies downgraded GoodRx from Buy to Hold and set a new price target of $2.75

    1/22/26 8:25:34 AM ET
    $GDRX
    EDP Services
    Technology

    Barclays initiated coverage on GoodRx with a new price target

    Barclays initiated coverage of GoodRx with a rating of Underweight and set a new price target of $3.00

    12/9/25 8:49:54 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/14/24 12:29:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/13/24 4:30:24 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/12/24 4:02:41 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Financials

    Live finance-specific insights

    View All

    GoodRx Reports First Quarter 2026 Results

    Pharma Direct Revenue Increased 82% Year-Over-Year in the First Quarter Company Raises Full Year 2026 Revenue and Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2026. First Quarter 2026 Highlights Revenue of $194.0 million Net income of $1.2 million; Net income margin of 0.6% Adjusted Net Income1 of $23.0 million; Adjusted Net Income Margin1 of 11.9% Adjusted EBITDA1 of $58.3 million; Adjusted EBITDA Margin1 of 30.0% Net cash provided by operating activities of $11.8 million "We deliver

    5/6/26 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for prescription savings in the U.S., today announced it will release its first quarter 2026 financial results after U.S. markets close on Wednesday, May 6, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 7, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor

    4/17/26 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for prescription savings in the U.S., today announced it will release its fourth quarter and full year 2025 financial results after U.S. markets close on Wednesday, February 25, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, February 26, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live

    1/28/26 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Leadership Updates

    Live Leadership Updates

    View All

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity

    Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for

    6/5/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

    Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

    3/17/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology